Testing a new medication for a rare immune disorder with skin and lupus symptoms

Plain-English translation of NCT07262983 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

What is this trial?

This is a safety study of a medication called in people with Job syndrome (a rare immune disorder) who also have lupus-like features and/or severe eczema. The study will track how well patients tolerate the medication and whether it helps reduce infections, skin symptoms, and lupus-related problems over 6 months. This medication works by adjusting how the immune system responds.

Job syndrome is a rare genetic immune disorder that makes people prone to serious infections and can cause lupus-like symptoms and severe eczema. There are very few treatment options available, and doctors need to find safer and more effective ways to help patients manage their symptoms and reduce infections.

Do you qualify?

You likely qualify if…

you are at least 12 years old
you have been diagnosed with Job syndrome caused by a STAT3 gene mutation
you have lupus-like symptoms and/or severe eczema (with an eczema severity score of 16 or higher)
you are able to take oral medication and commit to following the study plan
you are already enrolled in an NIH natural history study of this disease
if you can have children, you agree to use reliable contraception during the study

You likely don't qualify if…

you have ever had a serious allergic reaction to baricitinib or similar JAK inhibitors
you are currently taking rituximab or certain other strong immune-suppressing medications
you have participated in another experimental drug study within the last 6 months
you are taking methotrexate or mycophenolate mofetil without stopping for at least 90 days first
you are taking high doses of steroids (more than 10 mg of prednisone daily)

What participation looks like

You will first spend 3 months before the study officially starts tracking your infections and skin symptoms to make sure your disease is stable. Once the study begins, you'll take the medication by mouth for 6 months (180 days) and come in for visits to check for side effects, measure improvements in your skin and lupus symptoms, and watch for any changes in infections. The study team will carefully monitor your safety throughout.

Testing a new medication for a rare immune disorder with skin and lupus symptoms

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)